On 5 September 2008, orphan designation (EU/3/08/561) was granted by the European Commission to Kiadis Pharma Netherlands B.V, Netherlands, for donor lymphocyte preparation depleted of functional alloreactive T-cells for the prevention of Graft-versus-Host disease.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Donor lymphocyte preparation depleted of functional alloreactive T-cells
Prevention of graft-versus-host disease
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
EU/3/08/561: Public summary of positive opinion for orphan designationof donor lymphocyte preparation depleted of functional alloreactive T-cellsfor the prevention of Graft-versus-Host disease (PDF/212.37 KB)
First published: 24/04/2009
Last updated: 28/02/2022
EMEA/COMP/308922/2008 Rev. 1
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: